{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T15:41:18Z","timestamp":1762184478376,"version":"build-2065373602"},"reference-count":44,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Introduction: The aim of the study was to analyse the results and potential complications of local treatment with HDR (high dose-rate) brachytherapy of liver metastases from colorectal cancer, depending on the targeted therapy used and considering RAS gene mutation and chemotherapy in individual treatment lines. Material and methods: The study included 142 patients with oligoprogressive liver metastases who underwent HDR brachytherapy without changing the line of treatment, based on a retrospective analysis of 270 patients treated between 2015 and 2022. The impact of RAS gene mutations, lines of chemotherapy depending on the treatment regimens used, PFS (progression free survival), OS (overall survival), LC (local control) and the degree of radiological response were analysed. The impact of these drugs on hepatotoxicity and the risk of haemorrhagic complications was also analysed. Results: The presence of mutations in KRAS\/NRAS genes (exons 2, 3, 4) had a statistically significant impact on PFS in the first, third and fourth lines of treatment, and on OS and LC in the third and fourth lines of treatment. In the third and fourth lines of treatment, patients with a mutation in the RAS gene had a poorer radiological response to treatment regardless of the chemotherapy used. PFS, OS and LC differed depending on the line of treatment and amounted to 17.5, 11, 8.5, 6 and 4 months, 27, 19, 13, 11 and 11 months, and 27, 19, 11, 6 and 6 months, respectively. The greatest benefit in terms of PFS was achieved by patients treated with first-line chemotherapy combined with epidermal growth factor receptor (EGFR) inhibitors, in the absence of RAS gene mutations. In the third line, the greatest benefit was achieved by patients treated with trifluridine\/tipiracil in the absence of RAS gene mutations. The greatest percentage reduction in the volume of treated lesions and the highest percentage of control were observed in the first three lines of treatment. The toxicity of the treatment was low; only in the third and fourth lines of treatment were differences in the decrease in albumin levels found depending on the type of treatment used. Conclusions: A mutation in the RAS genes worsens the prognosis, regardless of the line of treatment and the systemic treatment used. The greatest benefit from brachytherapy is seen in patients in the first three lines of treatment without RAS mutations, treated with anti-EGFR chemotherapy in the first line and trifluridine\/tipiracil in the third line. Combining brachytherapy of liver metastases with systemic treatment is safe, regardless of the systemic treatment used.<\/jats:p>","DOI":"10.3390\/cancers17213530","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T14:40:48Z","timestamp":1762180848000},"page":"3530","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interventional Radiotherapy (Brachytherapy) Combined with Systemic Treatment\u2014The Influence of RAS Gene Mutations and Combined Therapy on the Results and Toxicity of Colorectal Cancer Liver Metastases"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8375-5289","authenticated-orcid":false,"given":"Pawe\u0142","family":"Cisek","sequence":"first","affiliation":[{"name":"Department of Radiotherapy, Medical University of Lublin, 20-081 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Koz\u0142owska","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Medical University of Lublin, 20-081 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludmi\u0142a","family":"Grzybowska-Szatkowska","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Medical University of Lublin, 20-081 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1200\/JCO.2008.19.9273","article-title":"Patients With Initially Unresectable Colorectal Liver Metastases: Is There a Possibility of Cure?","volume":"27","author":"Adam","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Lin, Y.-M., Paolucci, I., Brock, K.K., and Odisio, B.C. (2021). Image-Guided Ablation for Colorectal Liver Metastasis: Principles, Current Evidence, and the Path Forward. Cancers, 13.","DOI":"10.3390\/cancers13163926"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3892\/ol.2017.6167","article-title":"Effect of primary tumor location and tumor size on the response to radiotherapy for liver metastases from colorectal cancer","volume":"14","author":"Doi","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1007\/s12094-020-02375-x","article-title":"Stereotactic body radiation therapy for liver metastasis from colorectal cancer: Size matters","volume":"22","author":"Flamarique","year":"2020","journal-title":"Clin. Transl. Oncol."},{"key":"ref_5","first-page":"100815","article-title":"HDR brachytherapy versus robotic-based and linac-based stereotactic ablative body radiotherapy in the treatment of liver metastases \u2013 A dosimetric comparison study of three radioablative techniques","volume":"48","author":"Bilski","year":"2024","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1200\/JCO.22.01690","article-title":"Treatment of Metastatic Colorectal Cancer: ASCO Guideline","volume":"41","author":"Morris","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Davis, T.B., Gupta, S., Yang, M., Pflieger, L., Rajan, M., Wang, H., Thota, R., Yeatman, T.J., and Pledger, W.J. (2022). Ras Pathway Activation and MEKi Resistance Scores Predict the Efficiency of MEKi and SRCi Combination to Induce Apoptosis in Colorectal Cancer. Cancers, 14.","DOI":"10.3390\/cancers14061451"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10585-025-10348-z","article-title":"EORTC\/ESTRO defined induced oligopersistence of liver metastases from colorectal cancer-outcomes and toxicity profile of computer tomography guided high-dose-rate brachytherapy","volume":"42","author":"Cisek","year":"2025","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Cisek, P., Kordzi\u0144ska-Cisek, I., and Grzybowska-Szatkowska, L. (2025). The role of brachytherapy in liver metastases from colorectal cancer. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1641533"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.radonc.2011.03.005","article-title":"Treatment of hepatic metastases of breast cancer with CT-guided interstitial brachytherapy\u2014A phase II-study","volume":"100","author":"Wieners","year":"2011","journal-title":"Radiother. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.ijrobp.2003.09.024","article-title":"CT-guided interstitial brachytherapy of liver malignancies alone or in combination with thermal ablation: Phase I\u2013II results of a novel technique","volume":"58","author":"Ricke","year":"2004","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1007\/s00330-015-3660-0","article-title":"CT-guided Interstitial Brachytherapy of Hepatocellular Carcinoma before Liver Transplantation: An Equivalent Alternative to Transarterial Chemoembolization?","volume":"25","author":"Denecke","year":"2015","journal-title":"Eur. Radiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"100811","DOI":"10.1016\/j.phro.2025.100811","article-title":"Comparison of interstitial high-dose-rate brachytherapy and stereotactic radiotherapy in breath-hold technique for inoperable primary and secondary liver tumors","volume":"35","author":"Geissler","year":"2025","journal-title":"Phys. Imaging Radiat. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13014-021-01812-7","article-title":"Comparison of liver exposure in CT-guided high-dose rate (HDR) interstitial brachytherapy versus SBRT in hepatocellular carcinoma","volume":"16","author":"Walter","year":"2021","journal-title":"Radiat. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s00066-016-0957-0","article-title":"Radioablation of liver malignancies with interstitial high-dose-rate brachytherapy","volume":"192","author":"Mohnike","year":"2016","journal-title":"Strahlenther. Onkol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3857\/roj.2020.00472","article-title":"Prospective evaluation of fiducial marker placement quality and toxicity in liver CyberKnife stereotactic body radiotherapy","volume":"38","author":"Dutta","year":"2020","journal-title":"Radiat. Oncol. J."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Cisek, P., Kuncman, \u0141., Jereczek-Fossa, B.A., Wojtyna, E., Orzechowska, M., Sroka, S., Kordzi\u0144ska-Cisek, I., Fijuth, J., and Bilski, M. (2025). Computed tomography guided high dose rate brachytherapy for induced oligoprogression of colorectal cancer liver metastases. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-09227-0"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"S\u00fctc\u00fco\u011flu, O., Y\u0131ld\u0131r\u0131m, H.\u00c7., Almuradova, E., G\u00fcnen\u00e7, D., and Yal\u00e7\u0131n, \u015e. (2025). RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches. Medicina, 61.","DOI":"10.3390\/medicina61071202"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"11067","DOI":"10.1093\/nar\/gkab871","article-title":"Oncogenic KRAS drives radioresistance through upregulation of NRF2-53BP1-mediated non-homologous end-joining repair","volume":"49","author":"Yang","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e482","DOI":"10.1016\/j.ijrobp.2021.07.1336","article-title":"Comparison of SBRT for Oligometastatic Colorectal Cancer by Site: Lung vs. Liver","volume":"111","author":"Winter","year":"2021","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.radonc.2020.08.012","article-title":"Superior outcomes of nodal metastases compared to visceral sites in oligometastatic colorectal cancer treated with stereotactic ablative radiotherapy","volume":"151","author":"Smith","year":"2020","journal-title":"Radiother. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"djx031","DOI":"10.1093\/jnci\/djx031","article-title":"Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype","volume":"109","author":"Hong","year":"2017","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.radonc.2020.02.008","article-title":"Association of tumor genomic factors and efficacy for metastasis-directed stereotactic body radiotherapy for oligometastatic colorectal cancer","volume":"146","author":"Jethwa","year":"2020","journal-title":"Radiother. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000454685","article-title":"Treatment Options in Oligometastatic Disease: Stereotactic Body Radiation Therapy-Focus on Colorectal Cancer","volume":"33","author":"Wild","year":"2017","journal-title":"Visc. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.lungcan.2018.08.005","article-title":"Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: Delaying the need to start or change systemic therapy?","volume":"124","author":"Lara","year":"2018","journal-title":"Lung Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Karagiannis, E., Strouthos, I., Leczynski, A., Zamboglou, N., and Ferentinos, K. (2022). Narrative Review of High-Dose-Rate Interstitial Brachytherapy in Primary or Secondary Liver Tumors. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.800920"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ijrobp.2009.09.026","article-title":"Local Response and Impact on Survival After Local Ablation of Liver Metastases From Colorectal Carcinoma by Computed Tomography\u2013Guided High-Dose-Rate Brachytherapy","volume":"78","author":"Ricke","year":"2010","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_29","first-page":"606","article-title":"Unresectable Colorectal Liver Metastases: Percutaneous Ablation Using CT-Guided High-Dose-Rate Brachytherapy (CT-HDBRT)","volume":"186","author":"Collettini","year":"2014","journal-title":"Rofo-Fortschritte Auf Dem Geb. Der Rontgenstrahlen Und Der Bild. Verfahr."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13014-018-0969-2","article-title":"Stereotactic Body Radiotherapy (SBRT) for liver metastasis\u2013clinical outcomes from the international multi-institutional RSSearch\u00ae Patient Registry","volume":"13","author":"Mahadevan","year":"2018","journal-title":"Radiat. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e12601","DOI":"10.1097\/MD.0000000000012601","article-title":"Curative-intent radiotherapy in patients with oligometastatic lesions from colorectal cancer","volume":"97","author":"He","year":"2018","journal-title":"Medicine"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Ji, X., Zhao, Y., Zhu, X., Shen, Z., Li, A., Chen, C., and Chu, X. (2021). Outcomes of Stereotactic Body Radiotherapy for Metastatic Colorectal Cancer With Oligometastases, Oligoprogression, or Local Control of Dominant Tumors. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.595781"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.radonc.2017.01.013","article-title":"Stereotactic body radiotherapy for oligo-metastatic liver disease\u2013Influence of pre-treatment chemotherapy and histology on local tumor control","volume":"123","author":"Klement","year":"2017","journal-title":"Radiother. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00066-017-1204-z","article-title":"Breathing-motion-compensated robotic guided stereotactic body radiation therapy","volume":"194","author":"Stera","year":"2017","journal-title":"Strahlenther. Onkol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s41199-016-0020-y","article-title":"Radiotherapy plus EGFR inhibitors: Synergistic modalities","volume":"2","author":"Bossi","year":"2017","journal-title":"Cancers Head Neck"},{"key":"ref_36","first-page":"75","article-title":"The dogma of Cetuximab and Radiotherapy in head and neck cancer\u2014A dawn to dusk journey","volume":"34","author":"Krishnamurthy","year":"2022","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Goedegebuure, R.S.A., de Klerk, L.K., Bass, A.J., Derks, S., and Thijssen, V.L.J.L. (2019). Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.03107"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.canlet.2020.08.038","article-title":"Radiosensitisation and enhanced tumour growth delay of colorectal cancer cells by sustained treatment with trifluridine\/tipiracil and X-rays","volume":"493","author":"Rothkamm","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2147\/IJN.S290438","article-title":"Application of Radiosensitizers in Cancer Radiotherapy","volume":"16","author":"Gong","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Vaugier, L., Mirabel, X., Martel-Lafay, I., Racadot, S., Carrie, C., Vendrely, V., Mah\u00e9, M.-A., Senellart, H., Raoul, J.-L., and Campion, L. (2021). Radiosensitizing Chemotherapy (Irinotecan) with Stereotactic Body Radiation Therapy for the Treatment of Inoperable Liver and\/or Lung Metastases of Colorectal Cancer. Cancers, 13.","DOI":"10.3390\/cancers13020248"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial","volume":"38","author":"Palma","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Pericay, C., Montes, A.F., Ordu\u00f1a, V.A., Declara, I.M., Mart\u00ednez, E.A., Salas, N.R., Torres, E., Lav\u00edn, D.C., Alonso, R.M.R., and Falc\u00f3, E. (2023). Real-World Outcomes in Patients with Metastatic Colorectal Cancer in Spain: The RWD-ACROSS Study. Cancers, 15.","DOI":"10.3390\/cancers15184603"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"100153","DOI":"10.1016\/j.esmorw.2025.100153","article-title":"Real-world treatment patterns and survival in patients with synchronous and metachronous metastatic colorectal cancer in the Netherlands","volume":"8","author":"Elferink","year":"2025","journal-title":"ESMO Real World Data Digit. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2147\/CMAR.S45193","article-title":"Anti-VEGF agents in metastatic colorectal cancer (mCRC): Are they all alike?","volume":"5","author":"Saif","year":"2013","journal-title":"Cancer Manag. Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/21\/3530\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T14:57:20Z","timestamp":1762181840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/21\/3530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":44,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["cancers17213530"],"URL":"https:\/\/doi.org\/10.3390\/cancers17213530","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2025,10,31]]}}}